Therapeutic Drug Monitoring
Affinergy has developed pairs of capture and detection reagents which are particularly well-suited to developing assays for diagnostic targets that are problematic for traditional antibody-based approaches (e.g. low immunogenicity, highly conserved target, etc.).
The capture reagent binds an analyte from a patient specimen (whole blood, plasma, serum) and the analyte is then directly detected through binding of a locking and detection reagent, which only recognizes the analyte when in complex with the capture reagent.
Peptide-mediated Cell Capture on Slides
Patient specimens come in a variety of biofluids (blood, sputum, saliva, fine-needle aspirate, urine). Depending on the specimen composition, Affinergy's cell-specific peptides can be added to the patient specimen directly or covalently attached to glass slides.
Affinergy has already developed peptides capable of recognizing mesenchymal stem cells, urothelial cells, and podocytes with high affinity and specificity. Peptide-mediated capture onto a slide's capture zone allows the rapid enrichment and concentration of a cell type of interest, while separating away cell types that are obscuring or irrelevant.
Affinergy's products are not currently approved by the U.S. Food and Drug Administration.